Catalyst Pharmaceuticals Overview
Catalyst Pharmaceuticals (CPRX) has a ROE of 21.85%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow21.85%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Catalyst Pharmaceuticals (CPRX) currently reports a ROE of 21.85%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Catalyst Pharmaceuticals's ROE history and peer comparisons.
Catalyst Pharmaceuticals's ROE of 21.85% is higher than the Healthcare sector average of -100.59%. That is roughly 121.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Catalyst Pharmaceuticals's current 21.85% should be judged against Healthcare norms (sector average: -100.59%) and against CPRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 21.85%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Catalyst Pharmaceuticals, and consider following CPRX for alerts when major investors trade the stock.
Catalyst Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 21.85% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CPRX with unrelated industries.
